Subscribe to Search results

Figures provided by Travenol in support of a product licence application for Proplex referred to a plasma pool size of approximately 6,000 litres; the number of donations was not specified, but would have been higher.

Published on:

During a product licensing application for Koate, Cutter noted that a pool consisted of 2,500 litres of plasma and approximately 4,000 human units or more, and from equal donations of at least 1000 individual donors. A given lot of Koate was usually made up from material fractionated from 3 to 5 pools.

Published on:

In a letter regarding a donor who had been diagnosed with AIDs, Dr Akin argued that the large pool dilution of the donor's plasma made it highly unlikely that transmission would occur to a recipient. It was also estimated that each pool contained plasma from as many as 7,000 to 15,000 individuals.

Published on:

In a letter to three British doctors, Linda Frith of the UK subsidiary of Cutter stated that Koate HT was prepared from pooled human plasma of at least 1,000 healthy donors.

Published on:

In an application for a renewal of the Koate HT product licence, it was noted that the product was prepared from pooled human plasma of at least 1,000 healthy donors.

Published on:

A study conducted on the Alpha heat-treated variant Profilate recorded that it was produced from plasma pools of between 5,000 amd 32,000 donors per batch.

Published on:

A report included in the initial product licence application for Kryobulin by Serological Products Ltd recorded that the pool size used was 1,000 donors between the ages of 18 and 65, whose plasma was obtained from centres in Austria and West Germany.

Published on:

The figure of 1,000 donors appeared on a product label for Kryobulin Red (made with European plasma) in the mid 1970s.

Published on:

The figure of 1,000 donors appeared on a draft product label for Prothromplex.

Published on:

The draft label provided with the product licence application for heat-treated Kryobulin did not give a donor pool size figure.

Published on:

At an NIBSC Infectious Hazards of Blood Products meeting Dr Rodell gave a summary of the commercial pool sizes and stated that one donor probably would not contribute more than four units to a particular pool.

Published on:

Hepatitis B tests were not sufficiently sensitive to detect every infected unit for over a decade after screening first became available.

Published on:

Dr John Craske's article "An Outbreak of Hepatitis Associated with Intravenous Injection of Factor-VIII Concentrate" was published in The Lancet. It said: "Testing the pooled plasma or the factor-VIII concentrate by the current radioimmunoassay techniques is not a reliable method of excluding hepatitis-B virus. Individual donations should be screened by R.I.A. before being pooled."

Published on:

Roderick Murray wrote the article "Viral Hepatitis", published in the Bulletin of the New York Academy of Medicine, which established that increasing pool sizes did not have the effect of dilution (and that any infectious particles would infect the whole pool).

Published on:

A report of the Meeting of Blood Products Advisory Committee on the Safety and Purity of Plasma Derivatives records that Dr Rodell warned that one donor infected with AIDS may make several contributions. He suggested that as few as four donors infected with AIDS could infect the whole world supply of factor concentrate.

Published on:

Marie Tatt wrote a letter to Elias Greene (and others) about the product licence application for Koate HS and requested that the existing "Warnings" statement (used in US markets) be amended for the UK. She wrote: "we would like to delete the reference to the Fletcher paper and potential transmission of Non-A, Non-B hepatitis".

Published on:

Elias Greene sent a fax to Marie Tatt stating that any labelling applied to products in the United States must contain the warning, and that where unlabelled products are sent, the recipient may prepare their own labels.

Published on:

The UK subsidiary of Travenol/Baxter was supplied with literature alongside the company's products, and that literature was initially drafted in the US. It was was then reviewed by the UK Regulatory Department to ensure compliance the current product licence requirements.

Published on:

A Koate product licence application discussed the addition of a warning about hepatitis.

Published on:

In a memo from Edward Cutter to Jack Ryan, Edward Cutter stated that it was advisable to include a warning about AIDs in literature about Factor IX and VIII products.

Published on: